Novo Nordisk lowered its sales and profit guidance as it contends with intensifying competition, pricing pressure and copycat versions of its weight-loss drugs

1 day ago 1

Intensifying competition, pricing unit and copycat versions of its weight-loss drugs are holding backmost income astatine the pharma giant.